ATAI Life Sciences BV (ATAI) is a Healthcare · Biotechnology company listed on NASDAQ. Price $7.35 (+0.82%), Market cap $1.49B, 52-week low–high $1.65 ~ $6.45.
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film
Financial statements, price targets, institutional (13F) holdings and related news for ATAI Life Sciences BV are updated in real time on BlackAll Trade.
ATAI Life Sciences BV trades at $7.35 (+0.82%). Real-time quotes and charts are available on BlackAll Trade.
ATAI Life Sciences BV has a market cap of about $1.49B.
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The com